Under the terms of the collaboration, Iktos will apply its generative AI and AI-orchestrated robotics platform to design, ...

A new study published in the journal Science Signaling has found that an immune system protein plays a central role in the ...

aims to advance oncology research by integrating computational design, medicinal chemistry, biology, medical science and ...

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

MindRank announced last month that it had initiated a Phase 3 clinical trial in China for MDR-001, a small molecule GLP-1 receptor agonists designed with the help of AI. GLP-1 rec ...

Under the terms of the agreement, Iktos will leverage its AI-driven generative design platform to accelerate the discovery of optimized small-molecule candidates against an undisclosed oncology target ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Veteran immunologist and former Pfizer R&D leader joins Circurna to advance its circular RNA therapeutic platform ...

ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to deliver potent, durable ...

Industry Trends and Global Forecasts, Till 2035" report has been added to ResearchAndMarkets.com's offering. The global GLP-1 market is estimated to grow from USD 62.2 billion in the current year to ...

The Gene Therapy R&D market presents robust opportunities, driven by clinical advancements in CAR-T therapies and a strong pipeline, particularly for cancer and rare diseases. Despite challenges from ...